Grifols SA ADR logo

Grifols SA ADR(GRFS)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 14 days
PROFIT SINCE LAST BUY
+7.28% ▲
LAST CLOSE
$8.69
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for GRFS

11/13/2026: GRFS (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Grifols SA ADR is a global healthcare company and leading producer of essential plasma-derived medicines and diagnostic solutions. The company's main business strengths lie in its vertically integrated collection network and robust demand for core biotherapies like immunoglobulins. Its primary investment story centers on margin optimization, operational streamlining, and disciplined balance sheet deleveraging. Key risks include historical debt burdens, collection cost inflation, and intense competition from major pharmaceutical rivals. The stock suits value-oriented investors willing to monitor ongoing debt reduction milestones and free cash flow generation.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile biopharma demand grows steadily, top-line acceleration is tempered by a strategic focus on margin optimization and debt reduction.
Momentum investorStrong fit while signal remains positivePositive earnings revisions and successful deleveraging milestones can attract short-term technical momentum when market sentiment improves.
Value investorStrong fitThe stock trades at attractive valuation multiples relative to normalized earnings power and asset replacement value.
Dividend investorWeak fitGrifols prioritizes cash preservation and debt service over high dividend yields.
Low-risk investorWeak fitHistorical capital structure complexities and regulatory headline risks introduce notable equity volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highThe ADR can experience sharp price swings driven by macro sentiment, governance headlines, and debt reduction progress.
Valuation riskMediumValuation is largely discounted due to past leverage concerns, creating recovery potential if execution remains steady.
Competition risk (plasma and biopharma)Medium / highIntense rivalry with well-capitalized global peers like CSL and Takeda pressures pricing and donor acquisition costs.
Business qualityStrongGrifols underpins essential healthcare infrastructure with deep technological barriers to entry.
Dividend incomeLowIncome-focused investors will find limited yield appeal given management's allocation toward deleveraging.
Execution riskMedium / highSuccessfully meeting strict deleveraging targets and cost-reduction goals is vital for sustained multiple expansion.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 5.91B USD
Price to earnings Ratio 10.47
1Y Target Price 10.37
Price to earnings Ratio 10.47
1Y Target Price 10.37
Volume (30-day avg) 693.2K shares
Beta 1.13
52 Weeks Range 6.87 - 9.64
Updated Date 11/15/2026
52 Weeks Range 6.87 - 9.64
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 0.83

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - General

BUY participation
77.8%
Active BUY / eligible
7 / 9
30-Day BUY Count Change
+4

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit -29.24%
Avg. Invested days 36
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
GRFS receives a 3-star rating, supported by solid company fundamentals, and solid quantitative characteristics. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
GRFS has solid overall fundamentals (4 stars), with solid financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+146.1%) and solid cash generation (FCF margin 10.4%) are partially offset by moderate revenue growth (+0.2%), soft profitability (net margin 5.3%), very low insider ownership of 0.92%.

Financial Health Rating

★★★★★
GRFS's financial health is supported by solid cash strength, including free-cash-flow generation (10.4% of revenue). Profitability is moderate (3 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is GRFS's strongest growth driver at +146.1% FY2025 versus FY2024 (strong, 5 stars). By comparison, free-cash-flow growth (+41.5%, strong) is also strong, while revenue growth (+0.2%, moderate) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 56.9% and approximately 323.9% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.92%, which materially reduces the ownership score.

Top 5 Institutional Investors

Brandes Investment Partners & Co 5.56%
Capital World Investors 3.37%
Permian Investment Partners 2.90%
Bank of America Corp 0.96%
Black Creek Investment Management Inc 0.94%

Unit Economics (Per $1K Revenue)

★★★★★
GRFS generates approximately $357 of gross profit, $164 of operating income, and $104 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Moderate margins and solid cash conversion support a 3-star rating, while capital efficiency is soft.

Economic Dimensions

★★★★★
Effective Tax Rate: 18.70%

Quantitative Style Profile

★★★★★
GRFS has a liquid profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedSmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Biopharma SegmentRevenues derived from plasma protein therapies including immunoglobulins, albumin, and specialty factors.This is the core profit engine of the company, providing essential therapies for chronic illnesses.
Diagnostic SegmentSales of blood-typing instruments, diagnostic reagents, and nucleic acid testing systems.Provides stable, recurring ancillary revenue through hospital and blood-bank testing contracts.
Bio Supplies & GeographyThird-party plasma sales and biological raw materials distributed across North America, Europe, and international markets.Diversifies operational cash flow across global healthcare markets.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-03
When -
Estimate 0.304
Actual 0.2739

Profitability

Profit Margin 6.44%
Operating Margin (TTM) 18.85%

Management Effectiveness

Return on Assets (TTM) 4.46%
Return on Equity (TTM) 7.33%

Valuation

Trailing PE 10.47
Forward PE 7.26
Enterprise Value 17.13B
Price to Sales(TTM) 0.78
Enterprise Value 17.13B
Price to Sales(TTM) 0.78
Enterprise Value to Revenue 2.04
Enterprise Value to EBITDA 9.45
Shares Outstanding 258.22M
Shares Floating 836.45M
Shares Outstanding 258.22M
Shares Floating 836.45M
Percent Insiders 0.92
Percent Institutions 56.94

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.